Evidence map›Paper›PMID 30621657›Full record

SynthesisBMC public health2019

Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions.

Angela R Bazzi, Mari-Lynn Drainoni, Dea L Biancarelli, Joshua J Hartman, Matthew J Mimiaga, Kenneth H Mayer, Katie B Biello

Abstract readSystematic Review
In one paragraph

Synthesis in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angela R BazziDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.
Mari-Lynn DrainoniDepartment of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA.
Dea L BiancarelliDepartment of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA.
Joshua J HartmanBoston Medical Center, Boston, MA, USA.
Matthew J MimiagaDepartments of Behavioral & Social Sciences and Epidemiology, Center for Health Equity Research, Brown University School of Public Health, Box G-S121-8, Providence, RI, 02912, USA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, USA.
Katie B BielloDepartments of Behavioral & Social Sciences and Epidemiology, Center for Health Equity Research, Brown University School of Public Health, Box G-S121-8, Providence, RI, 02912, USA. katie_biello@brown.edu.ORCID http://orcid.org/0000-0002-5017-5699

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
National Institute on Drug Abuse (US) K01DA043412NIAID NIH HHS P30 AI042853NIDA NIH HHS K01 DA043412Providence/Boston Center for AIDS Research collaborative developmental grant P30AI042853
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) are at increased risk for HIV acquisition and could benefit from antiretroviral pre-exposure prophylaxis (PrEP). However, PrEP has been underutilized in this population, and PrEP adherence intervention needs are understudied.

methodsTo inform PrEP intervention development, we reviewed evidence on antiretroviral therapy (ART) adherence among HIV-infected PWID. Guided by a behavioral model of healthcare utilization and using the PICOS framework, we conducted a systematic review in four electronic databases to identify original research studies of ART adherence in HIV-infected PWID in the United States and Canada between Jan 1, 2006-Dec 31, 2016. We synthesized and interpreted findings related to developing recommendations for PrEP adherence interventions for PWID.

resultsAfter excluding 618 duplicates and screening 1049 unique records, we retained 20 studies of PWID (mean n = 465) with adherence-related outcomes (via pharmacy records: n = 9; self-report: n = 8; biological markers: n = 5; electronic monitoring: n = 2). Predisposing factors (patient-level barriers to adherence) included younger age, female sex, and structural vulnerability (e.g., incarceration, homelessness). Enabling resources (i.e., facilitators) that could be leveraged or promoted by interventions included self-efficacy, substance use treatment, and high-quality patient-provider relationships. Competing needs that require specific intervention strategies or adaptations included markers of poor physical health, mental health comorbidities (e.g., depression), and engagement in transactional sex.

conclusionsHIV treatment adherence research carries important lessons for efforts to optimize PrEP adherence among PWID. Despite limitations, this systematic review suggests that strategies are needed to engage highly vulnerable and marginalized sub-groups of this underserved population (e.g., younger PWID, women who inject drugs) in PrEP adherence-related research and programming.

Indexed as

Anti-Retroviral AgentsCanadaHIV InfectionsHumansPre-Exposure ProphylaxisRandomized Controlled Trials as TopicSubstance Abuse, IntravenousTreatment Adherence and ComplianceUnited StatesAnti-Retroviral AgentsAdherenceAntiretroviral therapyDrug usePeople who inject drugsPre-exposure prophylaxisPrevention

Identifiers

PMID30621657
PMCPMC6323713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.